Group 1: Financial Performance - The company reported a total revenue of 464.53 million yuan for 2025, representing a year-on-year increase of 12.43% [1] - The net profit attributable to the parent company was 51.15 million yuan, showing a decline of 1.76% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 23.66 million yuan, significantly increasing compared to 2024 [1] - The growth in performance was primarily driven by overseas revenue, which increased by over 40% and accounted for more than 30% of total revenue [1] - In domestic operations, the usage of pressure monitoring radiofrequency ablation catheters increased by over 70%, contributing to the upgrade of high-end procedures [1] Group 2: Recent Events - The company announced on February 10, 2026, that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter received EU Medical Device Regulation (MDR) certification, facilitating entry into the European market and enhancing its overseas technology matrix [2] - On February 11, 2026, the company disclosed that approximately 346 million shares of restricted stock will be released for trading on March 2, 2026, representing 73.47% of the total share capital, which may exert liquidity pressure on the stock price [2] Group 3: Stock Performance - The stock price experienced fluctuations, closing at 23.50 yuan on February 12, 2026, with a 7-day price change of 0.95% and a volatility of 4.64% [3] - The stock dropped by 1.43% on February 11, 2026, the day the earnings report was disclosed, with a trading volume of 58.88 million yuan [3] - On February 12, 2026, the net outflow of funds from major investors was 5.11 million yuan, while retail investor activity remained high [3] - The medical device sector declined by 0.83% during the same period, underperforming the broader market [3]

Core Viewpoint - Microelectrophysiology has recently announced that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter have obtained the EU Medical Device Regulation (MDR) certification, which will facilitate the company's entry into the European market and enhance its overseas revenue through high-value-added products [1] Group 1 - The certification will assist the company in expanding its overseas revenue scale [1] - The company aims to enhance its overseas "mapping + ablation" technology matrix [1]

Important Matters - Evert plans to acquire 100% of Shengpu shares, with stock resuming trading on February 10 [1] - Hainan Mining intends to acquire 69.9% stake in Fengrui Fluorine Industry, with stock resuming trading on February 10 [1] - Runtou Co., which has seen its core product disperse dye prices rise by approximately 5000 yuan per ton recently, has achieved two consecutive trading limit increases [1] - Zhejiang Longsheng has announced another price adjustment for certain types of disperse dyes on February 8, with price sustainability dependent on supply and demand [1] - Taisheng Wind Power's rocket fuel storage tank production line is designed for an annual capacity of 60 tanks, expected to be operational by mid-2026 [1] - Dingsheng Technology has signed a cooperation framework agreement with Huineng Technology for solid-state batteries and the new energy industry [1] - Microelectrophysiology has received EU MDR certification for its magnetic navigation ablation catheter and star high-density mapping catheter [1] - Yuandong Bio has completed the first dosing of the Phase I clinical trial for the EP-0210 monoclonal antibody injection [1] - Xinyi Sheng has mass-produced and delivered 1.6T optical modules, while advancing the development of 3.2T, 6.4T, and 12.8T products [1] Investments, Contracts, and Collaborations - Mengguli plans to invest 929 million yuan to build a project for an annual production of 30,000 tons of lithium-ion battery cathode materials [1] - Zhiguang Electric's subsidiary has signed a 1.004 billion yuan contract for energy storage systems [1] - Daily Interaction's wholly-owned subsidiary intends to increase capital by 10 million yuan in Yuntong Shuda [1] - Jinhui Co. plans to acquire 100% of Fusheng Mining for 210 million yuan, which holds a gold mining right with an annual production capacity of 50,000 tons [1] - Yuanjie Technology intends to invest 1.251 billion yuan to build a second-phase research and production base for optoelectronic communication semiconductors, focusing on high-speed optical chips [1] - Zhongke Shuguang plans to issue convertible bonds to raise no more than 8 billion yuan for advanced computing cluster systems aimed at artificial intelligence [1] Share Buybacks - Huitai Medical plans to repurchase shares worth 150 million to 200 million yuan for employee stock ownership plans or equity incentives [2] - Kaiying Network intends to repurchase shares worth 100 million to 200 million yuan [2] - Dianzhi Technology plans to repurchase shares worth 100 million to 200 million yuan [2]

Group 1 - Huatai Medical plans to repurchase shares worth between 150 million to 200 million yuan for employee stock ownership plans or equity incentives, with a repurchase price not exceeding 315 yuan per share [1][3] - Aopt plans to raise no more than 1.38 billion yuan for projects related to AI intelligent vision solutions and industrial 3D vision sensors [1][4] - Weimais reported a net profit of 557 million yuan for 2025, a year-on-year increase of 39.22%, despite a slight decline in total revenue [1][6] Group 2 - Jiaokong Technology signed a contract for the Sydney Metro West Line TSMO signal system subcontract project, with a contract value of approximately 93.53 million Australian dollars [1][5] - Microelectrophysiology received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, facilitating entry into the European market [1][4] - Firmus Technologies, an Australian AI infrastructure company, secured 10 billion USD in debt financing led by Blackstone for data center expansion [8][9]

Core Viewpoint - The company has received the EU Medical Device Regulations (MDR) certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, enabling entry into the European market and enhancing overseas revenue growth [1] Group 1: Product Certification and Market Expansion - The certification of the magnetic navigation ablation catheter and star-shaped high-density mapping catheter supports the company's entry into the European market [1] - The high-value-added products will further expand the company's overseas revenue scale [1] Group 2: Technology and Competitive Advantage - The certification enhances the company's "mapping + ablation" technology matrix, forming a complete solution with the existing 3D mapping system [1] - This development strengthens the technical barriers of comprehensive energy ablation technology [1] Group 3: Customer Engagement and Brand Recognition - The precise, efficient, and safe product characteristics improve customer loyalty and solidify global brand recognition [1] - A strong foundation is laid for the rapid international expansion of the products [1]

Core Viewpoint - Microelectrophysiology has received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, which will facilitate entry into the European market and expand overseas revenue [1] Group 1: Product Certification - The company announced that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter have obtained EU MDR certification [1] - This certification is expected to enhance the company's overseas "mapping + ablation" technology matrix [1] Group 2: Market Impact - The entry into the European market is anticipated to increase the company's overseas revenue scale [1] - However, sales in international markets may be affected by uncertainties such as foreign regulatory policies, market environment changes, and exchange rate fluctuations [1] - The company is currently unable to predict the specific impact of these factors on its future business [1]

Core Viewpoint - The company has recently received the EU Medical Device Regulations (MDR) certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter [1] Group 1 - The magnetic navigation ablation catheter has been certified under the EU MDR [1] - The star-shaped high-density mapping catheter has also received certification under the EU MDR [1]